RT Journal Article
SR Electronic
T1 Menopause Hormone Replacement Therapy and Lifestyle Factors affect Metabolism and Immune System in the Serum Proteome of Aging Individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.22.24309293
DO 10.1101/2024.06.22.24309293
A1 Dierks, Clemens
A1 Mizrak, Roza Sürme
A1 Shomroni, Orr
A1 Farztdinov, Vadim
A1 Textoris-Taube, Kathrin
A1 Ludwig, Daniela
A1 Rainer, Johannes
A1 Mülleder, Michael
A1 Demuth, Ilja
A1 Ralser, Markus
YR 2024
UL http://medrxiv.org/content/early/2024/06/23/2024.06.22.24309293.abstract
AB Aging is a fundamental risk factor for a wide array of diseases. The Berlin Aging Study II (BASE-II) is a cohort study designed to investigate the physical, mental, and social determinants of successful aging. We utilized high-throughput mass spectrometry to measure the proteomes of 1890 BASE-II participants, divided into two age groups: 27-37 years and 60-85 years. We employed multiple linear regression analyses to explore the effects of demographic factors such as age, sex, and BMI, along with hormonal treatments and lifestyle factors, on the serum proteome. We identify new associations and confirm previously described proteins linked to age, sex, BMI and hormonal contraceptive use (HCU). Notably, we observed that the abundance of nutrient transport proteins, particularly apolipoproteins, is linked to metabolic diseases in aged individuals, including metabolic syndrome and type 2 diabetes. Additionally, we identified specific alterations explained by lifestyle factors, such as smoking and alcohol consumption. We further report a significant proteome signature in female study participants corresponding to menopause hormone replacement therapy (MHT). We successfully classified these participants based on MHT status with an AUROC of 0.82 using two proteins, Complement Component 9 and Plasminogen, slightly outperforming estradiol (AUROC: 0.80), the active ingredient in most MHT preparations. Overall, our study underscores the impact of lifestyle and hormonal therapies on the serum proteome during aging, primarily affecting components of the immune system and metabolism.Competing Interest StatementMarkus Ralser is founder and shareholder of Eliptica Ltd. Michael Muelleder is a consultant and shareholder of Eliptica Ltd.Funding StatementBASE-II was supported by the German Federal Ministry of Education and Research under grant numbers #01UW0808; #16SV5536K, #16SV5537, #16SV5538, #16SV5837, #01GL1716A, and #01GL1716B. This work was supported by a grant of the Deutsche Forschungsgemeinschaft (grant number 460683900 to ID). The proteomic work presented here was supported by the Ministry of Education and Research (BMBF), as part of the National Research Node 'Mass spectrometry in Systems Medicine' (MSCoresys), under grant agreement 031L0220 and 16LW023K, as well as the the German Cancer Consortium (DKTK) under agreement BE01 1020000483.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants gave written informed consent. The Ethics Committee of the Charite -Universitaetsmedizin Berlin approved the study (approval number EA2/029/09). The study was conducted in accordance with the Declaration of Helsinki and was registered in the German Clinical Trials Registry as DRKS00009277. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe raw mass spectrometry data of study pools and standardized, commercially available serum set samples, as well as the raw DIA-NN output and the FASTA file used for spectral library annotation, will be deposited in the ProteomeXchange Consortium via the PRIDE partner repository upon publication. To comply with data privacy rules, accessing human data requires a request to the access committee. Please contact the scientific coordinator, Ludmila Mueller, at lmueller{at}mpib-berlin.mpg.de for additional information about the procedures.